Cour Pharmaceuticals - Myasthenia Gravis Study

The main aim of this study is to see how safe and tolerable CNP-106, an investigational drug, is for people with Myasthenia Gravis. The study will help determine if CNP-106 can help improve your MG symptoms by reprogramming your immune system. All participants will receive CNP-106 or Placebo intravenously on Day 1, Day 8, and for some Day 90.